Karyopharm Therapeutics Inc at Jefferies Virtual London Healthcare Conference Transcript
Hi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. It's with great pleasure that I'd like to welcome the Karyopharm team with us today. We're going to do a fireside chat to talk about Karyopharm. And with us, we've got Michael Kauffman, the CEO; Mike Mason, the CFO; and Ian Karp from Investor Relations.
So thanks, everyone, for joining us today. And maybe to start off, Michael, if you want to provide an intro to Karyopharm for those who might not be familiar with the story.
Sure. Karyopharm was founded in 2009, focused on modulating nuclear export from the cell nucleus and treating diseases like cancer and other abnormalities, including autoimmune disease and certain viruses. We have our lead product, it's called XPOVIO. It's now marketed for 2 indications. It entered the clinic as selinexor, a first-in-class oral inhibitor of the nuclear export, protein
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |